ArticleScientific reports2017
Serum C3 and Renal Outcome in Patients with Primary Focal Segmental Glomerulosclerosis.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Genetically supported drug target prioritization for rare diseases.Genome medicine · 2026Article
- Pathogenesis of Focal Segmental Glomerulosclerosis and Minimal Change Disease: Insights from Glomerular Proteomics.Life (Basel, Switzerland) · 2025Article
- The Spectrum of Minimal Change Disease/Focal Segmental Glomerulosclerosis: From Pathogenesis to Proteomic Biomarker Research.International journal of molecular sciences · 2025Review
- Clinical and histopathological characteristics of primary focal segmental glomerulosclerosis in Turkish adults.Scientific reports · 2024Article
- Complement Activation in Nephrotic Glomerular Diseases.Biomedicines · 2024Review
- Develop and Validate a Risk Score in Predicting Renal Failure in Focal Segmental Glomerulosclerosis.Kidney diseases (Basel, Switzerland) · 2023Article
- Glomerular capillary C3 deposition as a risk factor for unfavorable renal outcome in pediatric primary focal segmental glomerular sclerosis.Frontiers in pediatrics · 2023Article
- Comparative proteomic analysis of children FSGS FFPE tissues.BMC pediatrics · 2022Article
- Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome.American journal of physiology. Renal physiology · 2021Article
- Microarray-based analysis of renal complement components reveals a therapeutic target for lupus nephritis.Arthritis research & therapy · 2021Article
- Loss of decay-accelerating factor triggers podocyte injury and glomerulosclerosis.The Journal of experimental medicine · 2020Article
- The role of hypertriglyceridemia and treatment patterns in the progression of IgA nephropathy with a high proportion of global glomerulosclerosis.International urology and nephrology · 2020Article
- Impact of Intravenous Iron on Oxidative Stress and Mitochondrial Function in Experimental Chronic Kidney Disease.Antioxidants (Basel, Switzerland) · 2019Article
- The Plethora of Angiotensin-Converting Enzyme-Processed Peptides in Mouse Plasma.Analytical chemistry · 2019Article
- Mesangial C4d deposition is independently associated with poor renal survival in patients with primary focal segmental glomerulosclerosis.Clinical and experimental nephrology · 2019Article
- Mesangial C4d deposition is independently associated with poor renal survival in patients with primary focal segmental glomerulosclerosis.Clinical and experimental nephrology · 2019Article
- C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis.JCI insight · 2019Article
- Renal Tubular Complement 3 Deposition in Children with Primary Nephrotic Syndrome.BioMed research international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of complement (C) in the pathogenesis or progression of focal segmental glomerulosclerosis (FSGS) is uncertain. The present study assessed the relationship between serum C3, the baseline characteristics, and the progression of FSGS in the cohort and identified the clinical implications of serum C3 levels in patients with FSGS. Compared to the patients with C3 ≥ 85 mg/dL (N = 474), those with C3 < 85 mg/dL (N = 117) presented a higher level of serum creatinine, lower levels of eGFR, hemoglobin, proteinuria, triglyceride, cholesterol, IgA, as well as, severe tubulointerstitial injury (TI). Of the 221 patients with a mean follow-up of 53.3 months, the risk of reaching end-stage renal disease (ESRD) was significantly higher in patients with low serum C3 level (p < 0.001). An additional 40 patients with primary FSGS revealed a significant correlation between MAC and AP (p = 0.003), MAC and serum C3 (p = 0.018), and AP and serum C3 (p = 0.028). Compared to patients with none-to-mild TI, those with moderate-to-severe TI exhibited a lower level of serum C3 and AP, and a higher level of serum MAC. In conclusion, complement activation occurring in patients with FSGS is associated with clinical and histological severities. Low serum C3 was an independent risk factor for poor renal outcome in patients with FSGS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.